Search | WHO COVID-19 Research Database

Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine.

Franceschi, J; Darrigade, A S; Sanchez-Pena, P; Legrain-Lifermann, V; Milpied, B.

J Eur Acad Dermatol Venereol ; 36(12): e969-e970, 2022 12.

Article in English | MEDLINE | ID: covidwho-2259516

Subject(s)

COVID-19 , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/etiology , COVID-19 Vaccines/adverse effects , RNA, Messenger , COVID-19/prevention & control , SARS-CoV-2

Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice.

Marniquet, M-E; Seneschal, J; Darrigade, A-S; Staumont-Sallé, D; Jachiet, M; Nosbaum, A; Tauber, M; Abasq, C; Ferrier Le Bouedec, M-C; Droitcourt, C; Aubert, H; Bernier, C; Soria, A; Raison-Peyron, N; Tétart, F; Aubin, F; Viguier, M; Valois, A; Kupfer-Bessaguet, I; Goronflot, T; Barbarot, S.

Br J Dermatol ; 186(4): 733-735, 2022 04.

Article in English | MEDLINE | ID: covidwho-1799276

Subject(s)

Dermatitis, Atopic , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Dermatitis, Atopic/drug therapy , Humans , Severity of Illness Index , Treatment Outcome

Subject(s)

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL